Use of drugs and dietary supplements to improve athletic performance is not just a problem for Olympians — these habits often start in adolescence. Teens are drawn in by ads that promise “natural” ways to enhance athleticism and give them an edge on the field.
Many of these supplements seem innocent enough, and their health claims are strong. Drug companies can’t advertise something that isn’t true, right?
Actually, the guidelines for marketing dietary supplements are quite lenient. Teens should be cautious when considering their use, and pediatricians should feel comfortable having open conversations with teen athletes and their parents about the risks associated with performance enhancing drugs.
Read Thriving’s lowdown on teens and dietary supplements.
Notes-worthy articles from around the web
U.S. News & World Report: Asthma researchers were puzzled to find that the condition is extremely rare in Amish communities, where children are exposed to more dust and allergens than children in typical American communities. A new study dives into this phenomenon and the results suggest some unconventional ways to prevent asthma.
New York Times: Implanting human stem cells into animal embryos is an ethically complicated scenario that sounds right out of science fiction. But the National Institutes of Health plans to lift its ban on these experiments in the not-too-distant future. Do the benefits outweigh the costs?
Reuters: The framing of gun violence as a public health issue is becoming less and less controversial. According to a recent survey, most Americans think it’s OK for doctors to talk with patients about guns: 30 percent said it should be saved for specific situations, while 23 percent said the conversation is appropriate any time.
Related reading: A Pediatrician’s View on Gun Violence and Children, a New York Times op-ed featuring Dr. Eric Fleegler, a pediatric emergency physician and health services researcher at Boston Children’s Hospital.
Learn more about Asthma, Allergy and Immunology research at Boston Children’s.
Where are all the pediatric clinical trials?
Two researchers at Boston Children’s Hospital found a disturbing trend when they searched for data on registered trails involving children.
Natalie Pica, MD and and Florence Bourgeois, MD, MPH took a retrospective, cross-sectional study of pediatric randomized clinical trials (RCTs) registered on ClinicalTrials.gov from 2008 to 2010 and found that 19 percent of were discontinued early. Of those that were actually completed, two thirds had still not published results after an average of 58 months.
Many studies do not publish data because technically, they are only required to report on Clinicaltrials.gov. However, without undergoing appropriate analysis, that data isn’t useful to others.
Our sister blog Vector spoke with Pica and Bourgeois to further investigate this disturbing trend and report on the various roadblocks facing pediatric RTCs.
Read Vector‘s coverage of unpublished pediatric trials.
Enrolling in a prospective study or clinical trial doesn’t always mean you’ll walk away with answers. But trials that sequence a patient’s genome can provide personalized results — and more and more such trials are doing so.
But how do people feel after getting this information? A new study examined the reactions of parents upon receiving genetic test results for their children with rare diseases.
Read more about this rare disease study on Vector.